Assessment of Synairgen’s drug in Covid-19 patients could signal a major breakthrough in the treatment patients.
Synairgen: shares soar of positive Covid-19 test results
The share price of Synairgen (LON: SNG), the AIM quoted respiratory drug discovery company, soared over 350% as it announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised Covid-19 patients.
The trial results showed that SNG001 greatly reduced the number of hospitalised Covid-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’. It also showed that patients who received…
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.